Drug Profile

OV 329

Alternative Names: OV-329

Latest Information Update: 24 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northwestern University
Developer Ovid Therapeutics
Class Antiepileptic drugs; Small molecules
Mechanism of Action 4-aminobutyrate transaminase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Epilepsy

Most Recent Events

11 Mar 2025 Adverse events data from the phase I trial in Epilepsy released by Ovid Therapeutics
11 Mar 2025 Pharmacodynamics and adverse events data from the preclinical studies in Epilepsy released by Ovid Therapeutics
11 Mar 2025 Ovid Therapeutics plans to initiate phase IIa patient study for OV 329 in drug resistant epilepsies in first quarter of 2026

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com